PharmiWeb2h
GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis
The GN-037 Phase 2 trial met the primary endpoint: treatment success, defined as the percentage of patients with at least a 2 ...
PharmiWeb2h
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US
Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), ...
PharmiWeb4h
Moolec Science to Host Fourth Quarter Fiscal Year 2024 Business Update Conference Call
Moolec Science SA (NASDAQ: MLEC; “Company”; “Moolec”), (NASDAQ: MLEC; “The Company”; “Moolec”) a science-based food ...
PharmiWeb37m
Gruber Plastic Surgery Dispels Misconceptions on Awake Surgeries
Dr. Meegan Gruber looks at myths vs. facts on safer, less invasive procedures.TAMPA, FL / ACCESSWIRE / September 25, 2024 / Awake surgery is becoming increasingly popular as patients seek safer, less ...
PharmiWeb2h
Univo IRB Launches Canadian Research Ethics Board Review Services for Clinical Trials in North America
Univo IRB, a leader in ethical review and oversight for clinical research, is proud to announce the launch of its Canadian research ethics board (REB) review services. This new offering is designed to ...
PharmiWeb2h
Santhera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular Dystrophy
Santhera Pharmaceuticals (SIX: SANN) announces that Swissmedic, the Swiss Agency for Therapeutic Products, has accepted for review the marketing authorization application (MAA) for AGAMREE® ...
PharmiWeb2h
Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary ...
PharmiWeb2h
AlgoTx Announces “Last Patient Last Visit” in International Phase II Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy
AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing a first-in-class therapeutic for peripheral neuropathic pain, ATX01, announced today the completion of the Last Patient Last ...
PharmiWeb1h
Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology
Orion Corporation and Aitia, an AI-enabled biotechnology company and the leader in the development and application of Causal AI and "Digital Twins" to discover and develop new drugs, announced today ...
PharmiWeb1h
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference
WOBURN, MA / ACCESSWIRE / September 25, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that ...
PharmiWeb1h
Semaglutide improves outcomes for obese patients with common skin condition, new study shows
Amsterdam, Netherlands) A pioneering study, presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in ...
PharmiWeb1h
Royal Columbian Hospital Foundation’s Advancing In…
Treatment of patients in intensive care units (ICUs) would significantly expand Ondine’s market opportunity.Infection prevention is a top priority in ICUs as they face higher infection rates, more ...